Literature DB >> 33469575

Coronavirus (COVID-19): A Systematic Review and Meta-analysis to Evaluate the Significance of Demographics and Comorbidities.

Arinjita Bhattacharyya, Anand Seth, Niharika Srivast, Michael Imeokparia, Shesh Rai.   

Abstract

Background The unprecedented outbreak of a contagious respiratory disease caused by a novel coronavirus has led to a pandemic since December 2019, claiming millions of lives. The study systematically reviews and summarizes COVID-19's impact based on symptoms, demographics, comorbidities, and demonstrates the association of demographics in cases and mortality in the United States.Methods PubMed and Google Scholar were searched from December 2019- August 2020, and articles restricted to the English language were collected following PRISMA guidelines. US CDC data was used for establishing statistical significance of age, sex, and race.Results• Among 3745 patients in China, mean age is 50.63 (95% CI: 36.84, 64.42) years, and 55.7 % (95% CI: 52.2, 59.2) were males. Symptoms included fever 86.5% (82.7, 90.0), fatigue 41.9% (32.7, 51.4), dyspnea 29.0% (21.2, 37.5), cough 66.0% (61.3, 70.6), mucus 66% (61.3, 70.6), lymphopenia 18.9% (5.2, 38.0). Prevalent comorbidities were hypertension 16.4% (12.5, 20.8), diabetes 8.9% (7.0, 11.1), CVD 10.9% (6.1, 16.7), ARDS 14.6% (4.9, 27.8), malignancy 1.5 ( 0.05, 2.8), 1.3% (0.08, 1.9), COPD 1.3 (0.08, 1.9). 63.5 % (33.5, 88.7) received oxygen therapy, 20.8% (8.9, 35.7) were in ventilation, 23.5% (5.9, 47.8) were at the ICU. 86.5% (76.8, 94) had antiviral, 73.9% (55.3, 89.0) had antibiotics, 30% (20.6, 40.2) corticosteroids treatment.• In the US, the odds ratio of infection in males to females is 0.873 (CI: 0.052,14.791), while the odds of dying from infection is 1.378 (CI: 0.081, 23.528) for males. The prevalence of infection is higher in females; case and death rates are higher in whites and Hispanics than other races; the death rate is higher in males irrespective of race and age; death rate per 100,000 population increases monotonically with age.Conclusion Results showed that metabolic diseases comprising CVD, diabetes, hypertension, and respiratory diseases, including COPD, ARDS, are the most common comorbidities to severe condition and poor prognosis in covid-19 patients. Following the recent FDA's guidance for designing Covid-19 vaccine trials, stratification factors of age, race, sex, and comorbidities need consideration in allocation. This study aimed to provide clinical researchers, health policy planners a detailed insight into the coronavirus disease.

Entities:  

Year:  2021        PMID: 33469575      PMCID: PMC7814834          DOI: 10.21203/rs.3.rs-144684/v1

Source DB:  PubMed          Journal:  Res Sq


  93 in total

1.  Developing Covid-19 Vaccines at Pandemic Speed.

Authors:  Nicole Lurie; Melanie Saville; Richard Hatchett; Jane Halton
Journal:  N Engl J Med       Date:  2020-03-30       Impact factor: 91.245

Review 2.  Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.

Authors:  James M Sanders; Marguerite L Monogue; Tomasz Z Jodlowski; James B Cutrell
Journal:  JAMA       Date:  2020-05-12       Impact factor: 56.272

3.  Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.

Authors:  L Zhang; F Zhu; L Xie; C Wang; J Wang; R Chen; P Jia; H Q Guan; L Peng; Y Chen; P Peng; P Zhang; Q Chu; Q Shen; Y Wang; S Y Xu; J P Zhao; M Zhou
Journal:  Ann Oncol       Date:  2020-03-26       Impact factor: 32.976

4.  Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic.

Authors:  Timothy P Hanna; Gerald A Evans; Christopher M Booth
Journal:  Nat Rev Clin Oncol       Date:  2020-05       Impact factor: 66.675

Review 5.  A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.

Authors:  Humaid O Al-Shamsi; Waleed Alhazzani; Ahmad Alhuraiji; Eric A Coomes; Roy F Chemaly; Meshari Almuhanna; Robert A Wolff; Nuhad K Ibrahim; Melvin L K Chua; Sebastien J Hotte; Brandon M Meyers; Tarek Elfiki; Giuseppe Curigliano; Cathy Eng; Axel Grothey; Conghua Xie
Journal:  Oncologist       Date:  2020-04-27

6.  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

Authors:  Bin Cao; Yeming Wang; Danning Wen; Wen Liu; Jingli Wang; Guohui Fan; Lianguo Ruan; Bin Song; Yanping Cai; Ming Wei; Xingwang Li; Jiaan Xia; Nanshan Chen; Jie Xiang; Ting Yu; Tao Bai; Xuelei Xie; Li Zhang; Caihong Li; Ye Yuan; Hua Chen; Huadong Li; Hanping Huang; Shengjing Tu; Fengyun Gong; Ying Liu; Yuan Wei; Chongya Dong; Fei Zhou; Xiaoying Gu; Jiuyang Xu; Zhibo Liu; Yi Zhang; Hui Li; Lianhan Shang; Ke Wang; Kunxia Li; Xia Zhou; Xuan Dong; Zhaohui Qu; Sixia Lu; Xujuan Hu; Shunan Ruan; Shanshan Luo; Jing Wu; Lu Peng; Fang Cheng; Lihong Pan; Jun Zou; Chunmin Jia; Juan Wang; Xia Liu; Shuzhen Wang; Xudong Wu; Qin Ge; Jing He; Haiyan Zhan; Fang Qiu; Li Guo; Chaolin Huang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Dingyu Zhang; Chen Wang
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

Review 7.  Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations.

Authors:  Awadhesh Kumar Singh; Ritesh Gupta; Amerta Ghosh; Anoop Misra
Journal:  Diabetes Metab Syndr       Date:  2020-04-09

Review 8.  Vertical Transmission of Coronavirus Disease 19 (COVID-19) from Infected Pregnant Mothers to Neonates: A Review.

Authors:  Mojgan Karimi-Zarchi; Hossein Neamatzadeh; Seyed Alireza Dastgheib; Hajar Abbasi; Seyed Reza Mirjalili; Athena Behforouz; Farzad Ferdosian; Reza Bahrami
Journal:  Fetal Pediatr Pathol       Date:  2020-04-02       Impact factor: 0.958

Review 9.  Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs.

Authors:  Hui Luo; Qiao-Ling Tang; Ya-Xi Shang; Shi-Bing Liang; Ming Yang; Nicola Robinson; Jian-Ping Liu
Journal:  Chin J Integr Med       Date:  2020-02-17       Impact factor: 1.978

10.  Statistical design of Phase II/III clinical trials for testing therapeutic interventions in COVID-19 patients.

Authors:  Shesh N Rai; Chen Qian; Jianmin Pan; Anand Seth; Deo Kumar Srivastava; Aruni Bhatnagar
Journal:  BMC Med Res Methodol       Date:  2020-08-31       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.